TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06773091: An Open-Label, Single-Arm, Multicenter Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of NK042 Cell Injection (Universal NKR+NK) in Advanced Solid Tumors

Sponsor: Shanghai NK Cell Technology Co., LTD · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 76 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06773091 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06773091 Rescue Dossier →